Direkt zum Inhalt

Forster, Lisa ; Vallaster, Bernadette ; Hubmann, Alexander ; Bresinsky, Merlin Niklas ; Fuller, Jessica L. ; Shi, Ke ; Lapcinski, Ian P. ; Liu, Peng ; Yang, M. ; Strasser, Jessica M. ; Nelson, Kathryn M. ; John, Kristen ; Mudaliar, Deepti ; Wirth, Lukas ; Daschner, Jonas ; Pongratz, Herwig ; Ashe, Karen H. ; Walters, Michael A. ; Pockes, Steffen

Potent and Selective Caspase-2 Inhibitors: Biological Profiling, Structural Characterization, and Challenges of Molecular Instability

Artikel

Forster, Lisa , Vallaster, Bernadette, Hubmann, Alexander, Bresinsky, Merlin Niklas , Fuller, Jessica L. , Shi, Ke, Lapcinski, Ian P., Liu, Peng, Yang, M., Strasser, Jessica M., Nelson, Kathryn M., John, Kristen, Mudaliar, Deepti, Wirth, Lukas, Daschner, Jonas, Pongratz, Herwig, Ashe, Karen H., Walters, Michael A. und Pockes, Steffen (2026) Potent and Selective Caspase-2 Inhibitors: Biological Profiling, Structural Characterization, and Challenges of Molecular Instability. Journal of Medicinal Chemistry.

DOI zum Zitieren dieses Dokuments: 10.5283/epub.83191


Zusammenfassung

Caspase-2 (Casp2) has emerged as a promising therapeutic target for neurodegenerative diseases due to its role in pathological tau processing. Here, we designed and synthesized a series of 48 novel peptidomimetic Casp2 inhibitors organized into distinct structural classes. Compounds were evaluated for Casp2 inhibition and selectivity against Casp1, 3, 4, 5, 6, 7, 8, 9, and 10. Inhibitors ...

Caspase-2 (Casp2) has emerged as a promising therapeutic target for neurodegenerative diseases due to its role in pathological tau processing. Here, we designed and synthesized a series of 48 novel peptidomimetic Casp2 inhibitors organized into distinct structural classes. Compounds were evaluated for Casp2 inhibition and selectivity against Casp1, 3, 4, 5, 6, 7, 8, 9, and 10. Inhibitors Idc(hE)G(Dab)D-CHO (32) and Idc(hE)G((S)-Me-THIQ)D-CHO (33) exhibited low nanomolar potency and ≥537-fold selectivity over Casp3. These unprecedented scaffold modifications are consistent with preferred steric arrangements between the P2 and P3 positions. Biochemical assays demonstrated the blockade of tau truncation and impaired the formation of toxic Δtau314. High-resolution crystal structures of compounds 2 and 33 bound to Casp2 revealed binding interactions consistent with the observed SAR. Although Idc(hE)V((S)-Me-THIQ)D-CHO (3, MUR-65) showed favorable ADME and pharmacokinetic properties, limited membrane permeability, insufficient blood−brain barrier penetration, and P5 indoline instability remain key challenges for further development.



Beteiligte Einrichtungen


Details

DokumentenartArtikel
Titel eines Journals oder einer ZeitschriftJournal of Medicinal Chemistry
VerlagACS
Open Access ArtACS Hybrid
Datum7 November 2026
Veröffentlichungsdatum17 Nov 2026 10:22
InstitutionenChemie und Pharmazie > Institut für Pharmazie
Chemie und Pharmazie > Institut für Pharmazie > Lehrstuhl Pharmazeutische / Medizinische Chemie I (Prof. Elz)
Projekte
Gefördert von: Deutsche Forschungsgemeinschaft (DFG) (527849699)
Identifikationsnummer
WertTyp
10.1021/acs.jmedchem.6c01370DOI
Stichwörter / KeywordsCaspase-2; tau; selectivity; peptidomimetics; covalent reversible inhibitors; Alzheimer’s disease
Dewey-Dezimal-Klassifikation600 Technik, Medizin, angewandte Wissenschaften > 615 Pharmazie
StatusVeröffentlicht
BegutachtetJa, diese Version wurde begutachtet
An der Universität Regensburg entstandenJa
URN der UB Regensburgurn:nbn:de:bvb:355-epub-831915
Dokumenten-ID83191

Bibliographische Daten exportieren

Nur für Besitzer und Autoren: Kontrollseite des Eintrags

nach oben